Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab extension study for recurrent gout flares
NL-OMON34583Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of canakinumab and triamcinolone acetonide in gout (2 arms), sponsored by Novartis. Primary endpoints: Long-term safety and tolerability and Adverse effects. Started Aug 2010; status: active, not recruiting.
02
Drugs
canakinumabtriamcinolone acetonide
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON34583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34583.